This review looked at the results for six previous studies that collectively involved 2,675 prostate cancer patients. The authors concluded that starting ADT patients early with estramustine-based chemotherapy did not improve overall survival. However, docetaxel, when used early with ADT, did improve both overall survival and biochemical progress-free survival.
Ramos-Esquivel A, Fernandez C, Zeledon Z. 2016. Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. Urol Oncol [Epub ahead of print] 1 April 2016. www.ncbi.nlm.nih.gov/pubmed/27052629